ClinicalTrials.gg
Active, not recruitingNCT03971461Updated Nov 17, 2026Results posted

Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma

A Phase 2 interventional study of Lutathera in Meningioma, sponsored by NYU Langone Health. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by NYU Langone Health · Phase 2, Interventional, and Treatment

How we know

Updated Nov 17, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 129 studies in Meningioma with a site in United States — 27 open to participants now, 39 under way, 1 of them phase 3. Meningioma · United States.

Enrollment
51st of 107
32 · median 30
Started
2019
with 6 others
Phase 2
46 of 129
10 open now
Primary completion
2025-04
later than 3 of 37 live
Registered
93rd of 129
by date
Lead sponsor
3 of 129
NYU Langone Health

Among the 129 studies in Meningioma with a site in United States, this one is the 51st largest by enrollment of the 107 interventional ones that give a count, is one of 7 that started in 2019, is one of 46 in phase 2, reaches primary completion later than 3 of the 37 other live ones, and was the 93rd registered.

Meningioma

256 studies on the registry are indexed under Meningioma; 86 are open to participants now.

Browse Meningioma studies →

Open to participants now

27 of the 129 studies in Meningioma with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Meningioma studies recruiting now, 43 (65%) set no upper age limit and 9 (14%) stop at 75 or younger; 8 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Meningioma with a site in United States, or all of them as a file.
02

Study summary

This single arm, open-label study will evaluate the efficacy of Lutathera (177Lu-DOTATATE) administered intravenously every 8 weeks for a total of 4 doses in patients with progressive WHO I-III or residual high-risk Ga-DOTATATE PET-MRI positive meningioma. Ga-DOTATATE PET-MRI scans will be obtained prior to initiation of Lutathera treatment and 6 months after the initiation of Lutathera treatment. The latter will be performed within the 14 days prior to the last dose of Lutathera treatment.

03

Conditions studied

  • Meningioma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged ≥ 18 years.
  2. Performance Status ≥ 60.
  3. confirmed diagnosis WHO grade I-III meningioma:

    a. For grade I meningioma, subjects must have: i. Progressive disease after at least surgical resection and radiotherapy, as defined as an increase in size of the measurable primary lesion (bidirectional area) on imaging by 25% or more between scans separated by no more than 12 months.

    or ii. Progressive residual tumor after maximal safe resection, be located at or near critical organs at-risk and considered to be high-risk for radiation injury by the treating investigator. Prior external beam radiotherapy is not required for these subjects.

    b. For Grade II or III meningioma, subjects must have either: i. Progressive disease after at least surgical resection and radiotherapy, as defined as an increase in size of the measurable primary lesion (bi-directional area) on imaging by 25% or more between scans separated by no more than 12 months or ii. Residual after surgery without requirement of progression.

  4. Positive 68Ga-DOTATATE uptake on PET-MRI.

    1. Positive uptake is defined as uptake higher than the background and SUV ratios adjusted to the liver and spleen uptake (adopted from Krenning score).
    2. 68Ga-DOTATATE uptake in target lesions should be Krenning score ≥ 2.
  5. Presence of measurable disease defined as at least one lesion measuring ≥10 mm in at least one dimension by contrast-enhanced MRI performed within 30 days prior to study registration.
  6. Multifocal disease is allowed but is limited to ≤ 3 measurable intracranial mass lesions on the most recent post-contrast MRI.
  7. Any neurological symptoms must be stable for at least 28 days prior to enrollment and patients should not require to control neurological symptoms.
  8. There is no limit on the number of prior surgeries, radiation therapy, radiosurgery treatments or systemically administered therapeutic agents.
  9. For patients treated with external beam radiation, interstitial brachytherapy or radiosurgery, an interval ≥24 weeks must have elapsed from completion from these therapies to registration unless there is histopathologic confirmation of recurrent tumor or there is new enhancing tumor outside the radiation field (beyond the high dose region or the 80% isodose line).
  10. An interval of ≥28 days (or 5 half-lives, whichever is shorter) from prior cytotoxic chemotherapy (6 weeks from nitrosoureas), biologic agent, agent or any other systemic agent prescribed for the purpose of treating meningioma.
  11. An interval of ≥28 days from craniotomy and ≥7 days from stereotactic .
  12. Availability of a paraffin-embedded archival tumor block from most recent tumor resection sufficient to generate at minimum 8 unstained slides but preferably up to 25 unstained slides; or, if a paraffin tumor block is unavailable, at minimum 8 unstained slides but preferably up to 25 unstained slides.

    a. Positive SSTR2 expression in the most recent tumor specimen must be confirmed by central pathology review.

  13. Patients must be willing and able to undergo regular MRI scans of the brain.
  14. Patients must have recovered to grade ≤1 or pretreatment baseline from adverse events related to prior therapy (exclusions include alopecia, laboratory values listed per inclusion criteria, lymphopenia, sensory neuropathy ≤ grade 2, or other ≤ grade 2 not constituting a safety risk based on the investigator's judgment).
  15. Adequate organ and bone marrow function as defined below (within 21 days of treatment initiation):

    1. White blood cell (WBC) ≥ 2,000/mm3
    2. (ANC) ≥ 1,000/mm3
    3. count ≥ 75,000/mm3
    4. ≥ 8 gm/dL
    5. (SGOT)/ALT(SGPT) ≤ 3 x laboratory (ULN)
    6. (measured or calculated) ≥ 50 mL/min OR creatinine levels > 150 μMol/L (1.7 mg/dL)
    7. Total serum ≤ 3 X ULN (except participants with Gilbert's Syndrome, who can have a total bilirubin ≤ 5 X ULN)
    8. Serum albumin level of more than 3.0 g/dL, unless the value was within the normal range
  16. Women of (WOCBP) and men able to father a child must agree to use adequate (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in the study, she must inform her treating physician immediately.
  17. Able to understand and willing to sign an IRB approved written document.

Exclusion criteria

Exclusion Criteria

  1. Patients with a clinical diagnosis of NF2 (either by NIH or Manchester criteria) or with a molecular diagnosis of NF2.
  2. Patients with radiation-associated meningiomas.
  3. Receiving any other agent which would be considered as a treatment for the primary neoplasm. This includes treatment with Somatostatin LAR within 4 weeks prior to treatment, or any patient receiving treatment with short-acting Octreotide that cannot be interrupted for greater than 24 hours before treatment.
  4. Peptide receptor radionuclide therapy at any time prior to registration.
  5. Known to somatostatin analogues or any component of the 68Ga- DOTATATE or 177Lu-DOTATATE formulations.
  6. Known additional that is progressing or requires active treatment within 2 years of start of study drug. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and in situ cervical cancer that has undergone potentially curative therapy.
  7. Current or planned participation in another study of an investigational agent or investigational device.
  8. Active infection requiring intravenous therapy with antibiotics.
  9. Uncontrolled intercurrent illness including, but not limited to, (i.e. active) cardiovascular disease: cerebral vascular accident/stroke (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), congestive heart failure (≥ class II), unstable angina pectoris, or serious cardiac arrhythmia requiring medication.
  10. Known history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS).
  11. Active virus (HBV) or virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test is positive).
  12. Other severe acute or chronic medical or psychiatric conditions (within the past year) including recent or active suicidal ideation or behavior, or laboratory abnormalities that may increase the risk associated with study participation or treatment on study or may interfere with the interpretation of study results.
  13. Pregnant and/or breastfeeding patients. Women of (WOCBP) must have a negative pregnancy test within 14 days of study entry.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Lutathera

    Drug: Lutathera

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival at 6 Months (PFS-6)

    The percentage of patients who were alive and had not experienced disease progression or relapse within 6 months of starting treatment.

    Time frame: 6 Months

Secondary outcomes

  1. Overall Survival at 12 Months (OS-12)

    The percentage of patients alive exactly one year after the start of a treatment or the date of their diagnosis.

    Time frame: 12 months

  2. Overall Survival (OS)

    The percentage of patients alive exactly 2 years after the start of a treatment or the date of their diagnosis.

    Time frame: 2 Years Post Treatment

07

Results

Posted Nov 17, 2026

Participant flow

Participant flow — Overall Study
MilestoneLutathera
Started26
Completed14
Not completed12
Withdrew: Death5
Withdrew: Lost to follow-up1
Withdrew: Physician decision1
Withdrew: Withdrawal by subject2
Withdrew: Still in follow-up3

Outcome measures

PrimaryProgression Free Survival at 6 Months (PFS-6)

The percentage of patients who were alive and had not experienced disease progression or relapse within 6 months of starting treatment.

Time frame:
6 Months
Reported as:
Count of participants · Participants
Progression Free Survival at 6 Months (PFS-6)
ParticipantsLutathera
Progression Free Survival at 6 Months (PFS-6)10
SecondaryOverall Survival at 12 Months (OS-12)

The percentage of patients alive exactly one year after the start of a treatment or the date of their diagnosis.

Time frame:
12 months
Reported as:
Count of participants · Participants
Overall Survival at 12 Months (OS-12)
ParticipantsLutathera
Overall Survival at 12 Months (OS-12)9
SecondaryOverall Survival (OS)

The percentage of patients alive exactly 2 years after the start of a treatment or the date of their diagnosis.

Time frame:
2 Years Post Treatment
Reported as:
Count of participants · Participants
Overall Survival (OS)
ParticipantsLutathera
Overall Survival (OS)3

Adverse events

Collected over 30 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lutathera13/17 (76.5%)6/17 (35.3%)16/17 (94.1%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventLutathera
SeizureNervous system disorders2/17
Lower Gastrointestinal HemorrhageGastrointestinal disorders1/17
SyncopeNervous system disorders1/17
DiarrheaGastrointestinal disorders1/17
TremorNervous system disorders1/17
HeadacheNervous system disorders1/17
VomitingGastrointestinal disorders1/17
Lung InfectionInfections and infestations1/17
Sinus BradycardiaCardiac disorders1/17
Cerebral EdemaMusculoskeletal and connective tissue disorders1/17
Most frequent other events
Showing 10 of 55
Most frequent other events
EventLutathera
Lymphocyte count decreasedBlood and lymphatic system disorders11/17
AnemiaBlood and lymphatic system disorders8/17
White blood cell decreasedBlood and lymphatic system disorders8/17
FatigueGeneral disorders7/17
HyponatremiaMusculoskeletal and connective tissue disorders6/17
Platelet count decreasedBlood and lymphatic system disorders6/17
Aspartate Aminotransferase IncreasedInvestigations5/17
HyperkalemiaMetabolism and nutrition disorders4/17
Neutrophil Count DecreasedBlood and lymphatic system disorders4/17
Alanine aminotransferase increasedInvestigations4/17

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lutathera
Mean60 (51 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)Lutathera
Female11
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lutathera
Hispanic or Latino1
Not Hispanic or Latino13
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lutathera
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American1
White9
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(participants)Lutathera
United States14
08

Study locations

2 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Apr 2025, 71 months.

Results were first posted in Nov 2026, 1 year 6 months after primary completion. A results delay was requested in Apr 2026.

Of 37 phase 2 interventional studies under Meningioma, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 108. This study's 71 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2019
First posted
Jun 3, 2019
StartActual
May 15, 2019
Primary completionActual
Apr 18, 2025
CompletionEst.
Jan 2027
Results delay requested
Apr 18, 2026
Results first posted
Nov 17, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 17, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProgression Free Survival at 6 monthsMonths (PFS-6)Time frame: 6 Months
Nov 17, 2026
Documents
Secondary outcomes
1 edited, 2 removed, 1 description edited
What changed in the outcomes
  • EditedOverall Survival at 12 monthsMonths (OS-12)Time frame: 12 months
  • RemovedObjective Response Rate (ORR)Time frame: 12 months
  • RemovedProgression Free Survival (PFS)Time frame: 2 Years Post Treatment
  • DescriptionOverall Survival (OS): how it is measured was reworded
Nov 17, 2026
Show all 2 updates
  1. Nov 17, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProgression Free Survival at 6 monthsMonths (PFS-6)Time frame: 6 Months
    Secondary outcomes 1 edited, 2 removed, 1 description edited
    What changed in the outcomes
    • EditedOverall Survival at 12 monthsMonths (OS-12)Time frame: 12 months
    • RemovedObjective Response Rate (ORR)Time frame: 12 months
    • RemovedProgression Free Survival (PFS)Time frame: 2 Years Post Treatment
    • DescriptionOverall Survival (OS): how it is measured was reworded
    + 3 other changes: index terms, verification date and registry dates
  2. Sep 29, 2026
    Minor edits only
    + 3 other changes: index terms, verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03971461
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Jun 3, 2019
Start date
May 15, 2019
Primary completion
Apr 18, 2025
Completion
Jan 2027 (estimated)
Results posted
Nov 17, 2026
Last update
Nov 17, 2026

Study contacts

Erik Sulman, MD
principal investigator · New York Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium Lu 177 dotatate

Start the discussion